From Early Research Through Regulatory Submission and Beyond
We work across the full development lifecycle. Whether you need a translational strategy for an early-stage asset, a CRO to run your Phase I/II program, or a partner for federal public health research, our teams bring scientific depth, operational discipline, and access to patient populations that most organizations can’t reach.
Translational Research & Evidence Strategy
We help sponsors identify evidence gaps early and design studies that hold up through regulatory review and payer evaluation. Our work includes feasibility assessments, biomarker strategy, endpoint selection, and integrated evidence plans shaped by data from 25M+ patient records across underserved communities. Therapeutic areas include oncology, rare disease, and infectious disease.
Clinical Trial Services
Full-service CRO capabilities from pre-clinical studies through Phase II, with partnered Phase III/IV support. We handle protocol development, regulatory strategy, site management, patient recruitment, safety monitoring, data management, and biostatistics. Our mobile clinical sites extend trial access to communities that traditional site networks don’t reach, which is how we maintain 90% retention in hard-to-reach populations.
Federal Health & Public Health Research
We partner with federal agencies on infectious disease surveillance, biodefense programs, and community health initiatives. Our teams bring the same scientific rigor applied in commercial programs to national and community-level decision-making, combined with experience navigating federal contracting, culturally informed engagement strategies, and scalable research frameworks.
Better Evidence Starts With Better Data
Most clinical databases reflect a narrow slice of the patient population. When studies are designed on incomplete data, the gaps carry forward into regulatory filings, payer decisions, and clinical practice. Treatments reach the market without evidence from the communities that need them most. Rubix LS starts with the data others don’t have.
Our research programs draw on 25M+ integrated patient data sets representing communities, geographies, and disease presentations that are systematically absent from standard clinical databases.
The Scale Behind Our Work
Patient data sets integrated from underserved and underrepresented communities worldwide.
25M+
Trial retention rate in hard-to-reach populations, supported by mobile clinical sites and community-embedded research infrastructure.
90%
Research frameworks designed globally across oncology, rare disease, infectious disease, and public health.
50+
A Partner Built for Complex Programs
Integrated Teams, Not Handoffs
Your team stays consistent from study design through trial execution and data delivery. The scientists shaping your evidence strategy are connected to the operators running your trial.
Recent Work
See examples of how we design, execute, and scale evidence across therapeutic areas and program types, from investigator-led oncology studies to federal infectious disease programs.
